8-K: TuHURA Biosciences Reports Q1 2025 Financial Results and Provides Corporate Update, Anticipates Phase 3 Trial Initiation

TuHURA Biosciences announces its Q1 2025 financial results, highlights clinical trial advancements, and anticipates the closing of the Kineta, Inc. acquisition.

Summary

• TuHURA Biosciences reported its financial results for the first quarter ended March 31, 2025.
• The company anticipates initiating a Phase 3 trial of IFx-Hu2.0 for Merkel cell carcinoma in Q2 2025.
• A Phase 1b/2a trial of IFx-Hu2.0 as adjunctive therapy with pembrolizumab in first-line Merkel cell carcinoma of unknown primary origin (MCCUP) has been initiated.
• TuHURA is targeting to close the acquisition of Kineta, Inc. in Q2 2025 and initiate a Phase 2 trial of Kinetas VISTA inhibiting monoclonal antibody in NPM1-mutated acute myeloid leukemia (AML) in Q3 2025.
• Research and development expenses were $4.6 million for the three months ended March 31, 2025, compared to $3.6 million for the same period in 2024.
• General and administrative expenses were $2.4 million for the three months ended March 31, 2025, compared to $1.0 million for the same period in 2024.
• As of March 31, 2025, TuHURAs total shares outstanding was approximately 43.7 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical trials and a strategic acquisition. However, the need for additional financing and the inherent risks in forward-looking statements temper the overall sentiment.

Positives

• The Phase 3 trial of IFx-Hu2.0 has an SPA agreement with the FDA, potentially saving time and money.
• The acquisition of Kineta, Inc. will add a late-stage pipeline asset with the VISTA inhibitor antibody.
• The company is developing tumor microenvironment modulators, which could have broad implications for cancer treatment.
• Initiation of Phase 1b/2a study of IFx-Hu2.0 as adjunctive therapy to Keytruda in 1L MCCUP.
• Presentation of posters at the American Academy of Cancer Research (AACR) Annual Meeting.

Risks

• The closing of the Kineta acquisition is subject to financing and other conditions.
• The company needs additional capital to complete the Kineta merger.
• Forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

TuHURA anticipates several milestones in the near term, including initiating a Phase 3 trial for IFx-Hu2.0, closing the Kineta acquisition, and advancing the VISTA inhibitor into a Phase 2 trial. The company also plans to present non-clinical data on its ADC and APC development candidates.

Management Comments

• James Bianco, M.D., President and Chief Executive Officer of TuHURA Biosciences, stated that the company has had an impressive start to 2025 and continues to execute its corporate strategy.
• Dr. Bianco noted that evaluating IFx-Hu2.0 in MCCUP patients is an important component of the overall strategy for the program.
• Dr. Bianco stated that the company is moving towards initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 and anticipates resolving the manufacturing-related partial clinical hold in the coming weeks.
• Dr. Bianco stated that the company is targeting to close the acquisition of Kineta later this quarter and advance KVA12123 into a Phase 2 trial in relapsed or refractory NPM1-mutated AML.
• Dr. Bianco concluded that the company believes that its DOR program has the potential to reprogram the function of MDSCs and M2 macrophages within the tumor microenvironment.

Industry Context

TuHURA is focused on developing novel immunotherapies to overcome resistance to cancer treatments, a significant challenge in the oncology field. The acquisition of Kineta and its VISTA inhibitor antibody aligns with this strategy, as VISTA is an emerging target in immuno-oncology. The company's focus on tumor microenvironment modulators also reflects a growing interest in targeting the complex interactions within the tumor to improve treatment outcomes.

Comparison to Industry Standards

• TuHURAs approach of combining IFx-Hu2.0 with Keytruda (pembrolizumab) is similar to other combination immunotherapy strategies being explored by companies like Merck (the maker of Keytruda) and Bristol-Myers Squibb.
• The development of VISTA inhibitors puts TuHURA in competition with companies like Jounce Therapeutics and Compugen, which are also developing therapies targeting the VISTA pathway.
• TuHURAs focus on ADC and APC development candidates targeting MDSCs aligns with the broader industry trend of developing targeted therapies that modulate the tumor microenvironment, similar to efforts by companies like BioNTech and Adaptimmune.

Management Changes

Stakeholder Impact

• Shareholders may be impacted by the potential acquisition of Kineta and the progress of clinical trials.
• Employees may be affected by the integration of Kineta and changes in management structure.
• Patients with Merkel cell carcinoma and AML may benefit from the development of new therapies.

Next Steps

• Initiate Phase 3 accelerated approval trial of IFx-Hu2.0 in first-line Merkel cell carcinoma.
• Close the acquisition of Kineta, Inc.
• Initiate Phase 2 trial of VISTA inhibiting mAb in combination with a menin inhibitor for the treatment of NPM1-mutated AML.
• Present non-clinical data on ADC and APC development candidates at relevant medical meetings.

Key Dates

Keywords

TuHURA Biosciences, IFx-Hu2.0, Kineta, VISTA inhibitor, Merkel cell carcinoma, AML, Clinical trials, Acquisition, Financial results, Pembrolizumab, Immunotherapy